The US launch ofAbbott's next-generation fibrate product TriLipix (fenofibric acid) delayed-release capsules is imminent following its approval by the FDA for mixed dyslipidaemia. It will be co-promoted there by Abbott andSolvay Pharmaceuticals.
TriLipix is the first fibrate to be approved for use both as a monotherapy and in combination with a statin,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?